6.4.3 Drugs Affecting Bone Structure and Mineralisation

Romosozumab	This High-Cost Drug has been approved for the following indications: -For the treatment of severe osteoporosis, as per NICE Guidance below - Patients will remain under follow up with an osteoporosis clinic, the responsibility for choice and duration of subsequent treatment options post 12-month period will be decided in secondary care.
For more information and NICE Guidance Click Here	Romosozumab for treating severe osteoporosis NICE Guidance TA791

For shared care guidelines on Denosumab please click here

Pack
1 pre-filled disposable injection